Skip to main content

Too Few Cancer Patients Get Palliative Care When Urinary Blockages Arise

Medically reviewed by Carmen Pope, BPharm. Last updated on Dec 28, 2023.

By Carole Tanzer Miller HealthDay Reporter

THURSDAY, Dec. 28, 2023 -- The prognosis is poor for many cancer patients who develop serious urinary blockages, but researchers say less than half receive palliative care.

Palliative care aims to relieve pain and other symptoms of serious illness. Hospice care, one type of palliative care, is an option for patients who are expected to live no more than six months.

Hospice care can make patients comfortable and head off aggressive treatments for patients with malignant ureteral obstruction (MUO) who are nearing the end of life, said lead researcher Dr. Michael Felice, of Loyola University Medical Center in Maywood, Ill.

MUO is a serious blockage of the urinary tract caused by advanced cancer. It causes urine to accumulate in the kidneys, and while decompression treatments using stents or tubes can relieve the build-up, the prognosis is typically poor. The treatments are also invasive, complications are common and benefits are sometimes questionable, researchers report.

In the January issue of the journal Urology Practice, Felice's team looked at the use of palliative and hospice care among 115 MUO patients. They were diagnosed between 2014 and 2020.

Records showed that a minority of those patients -- 39% -- received palliative care. The average delay between MUO diagnosis and palliative care evaluation was two months. Researchers said just five of 45 patients were referred to palliative care before making decisions about decompression treatment.

"Earlier referral to palliative care might help to promote informed decisions about preferences for care among patients with MUO," Felice said in a journal news release.

In all, 54% of patients received hospice care. Median delay after MUO diagnosis was 144 days, meaning half entered hospice care sooner, half later. Once entering hospice, patients lived a median of 12 days.

Median time from MUO diagnosis to death was 141 days and survival was similar whether patients were in palliative care or not.

Of patients who died, the study found 43% had high use of health care, including repeated hospitalizations or emergency room visits. Of those who did not enter hospice, 86% had high end-of-life health care use.

"This highlights the impact of hospice in facilitating end-of-life discussion and enabling patients to decide how and where they spend their last days," the study said.

Hospice patients were 97% less likely to have high health care use at the end of their lives.

MUO patients "are ideal candidates for palliative care consultation, to help navigate the complexities of multidisciplinary care and guide decision-making," the authors wrote.

Because 8 in 10 study patients saw a urologist at some point during their MUO care, researchers said these specialists are well positioned to begin conversations about palliative care.

Sources

  • Wolters Kluwer Health, news release, Dec. 21, 2023

Disclaimer: Statistical data in medical articles provide general trends and do not pertain to individuals. Individual factors can vary greatly. Always seek personalized medical advice for individual healthcare decisions.

© 2024 HealthDay. All rights reserved.

Read this next

Current Gene Screens Miss Many at High Cancer Risk: Study

THURSDAY, July 19, 2024 -- As good as many genetic tests might be, a deeper look at the DNA of over 44,000 people identified many who carried genes that hike their risks for...

Ancient Viruses Might Be Spurring Modern-Day Cancers

FRIDAY, July 19, 2024 -- Cancer growth can be fueled by flecks of ancient viral DNA lodged into the genetics of modern humans, a new study says. Overall, about 8% of the human...

Late Cancer Diagnosis Biggest Health Concern for Most, Poll Shows

MONDAY, July 15, 2024 — When it comes to health worries, cancer leads the way, a new poll shows.  The University of Cambridge poll included 2,000 adults who said...

More news resources

Subscribe to our newsletter

Whatever your topic of interest, subscribe to our newsletters to get the best of Drugs.com in your inbox.